Citation Impact
Citing Papers
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
2006
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
2013 StandoutScience
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells
2002
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
2005
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-Negative Estrogen Receptor−/Progesterone Receptor−/HER-2− Breast Carcinomas
2007
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
Tipin-Replication Protein A Interaction Mediates Chk1 Phosphorylation by ATR in Response to Genotoxic Stress
2010 StandoutNobel
Determining cell type abundance and expression from bulk tissues with digital cytometry
2019 Standout
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
2008
A ruthenium polypyridyl intercalator stalls DNA replication forks, radiosensitizes human cancer cells and is enhanced by Chk1 inhibition
2016
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Targeting the ERK signaling pathway in cancer therapy
2006
The DNA Damage Response Kinases DNA-dependent Protein Kinase (DNA-PK) and Ataxia Telangiectasia Mutated (ATM) Are Stimulated by Bulky Adduct-containing DNA
2011 StandoutNobel
BRAFE600-associated senescence-like cell cycle arrest of human naevi
2005 StandoutNature
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation
2003
Farnesyltransferase inhibitors: promises and realities
2002
Detection of Peptides, Proteins, and Drugs That Selectively Interact With Protein Targets
2002 StandoutNobel
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
The ground state of embryonic stem cell self-renewal
2008 StandoutNature
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
2006
Vemurafenib in melanoma
2013
Ras history
2010
Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche
2004 Standout
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
2006
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Sorafenib
2006
Cancer genes and the pathways they control
2004 Standout
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
2004
BRAF Mutation in Papillary Thyroid Carcinoma
2003
Upstream and downstream of mTOR
2004 Standout
Conservation, Variability and the Modeling of Active Protein Kinases
2007 StandoutNobel
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
2006
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
2008 StandoutNature
Distinct Sets of Genetic Alterations in Melanoma
2005 Standout
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
2005
Oncomirs — microRNAs with a role in cancer
2006 Standout
Raf kinases: Oncogenesis and drug discovery
2006
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
2005
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
2003
BAY 43-9006 Inhibition of Oncogenic RET Mutants
2006
Targeting multiple signal transduction pathways through inhibition of Hsp90
2004
Targeting DNA repair mechanisms in cancer
2012
A Cytoplasmic NF-κB Interacting Long Noncoding RNA Blocks IκB Phosphorylation and Suppresses Breast Cancer Metastasis
2015
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
2008 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
2007 Standout
Drugging the undruggable RAS: Mission Possible?
2014
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx
2019 StandoutNobel
The genetics and genomics of cancer
2003
Short interfering RNAs as a tool for cancer gene therapy
2004
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
2010
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway– and microtubule-targeting inhibitors
2007
Mechanisms of drug inhibition of signalling molecules
2006 Nature
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
The role of microRNA genes in papillary thyroid carcinoma
2005 Standout
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
2003
Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma
2004
Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation
2017 StandoutNobel
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells
2005
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
2003
The future of immune checkpoint therapy
2015 StandoutScienceNobel
The selectivity of protein kinase inhibitors: a further update
2007 Standout
Missense mutations of the BRAF gene in human lung adenocarcinoma.
2002
V599EB-RAF is an Oncogene in Melanocytes
2004
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Works of Barbara Hibner being referenced
CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo
2007
Discovery of a novel Raf kinase inhibitor.
2001
Dominant negative mutants of mitogen-activated protein kinase pathway
2001